Compare ADMA Biologics Inc (ADMA) vs Cisco Systems Inc (CSCO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Cisco Systems Inc — how do they compare? ADMA Biologics Inc trades at $9.16 (market cap $2.13B), while Cisco Systems Inc trades at $113.73 (market cap $440.61B). The key difference: Cisco Systems Inc is far larger — about 206.9× ADMA Biologics Inc's market cap, and Cisco Systems Inc pays a 1.5% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | CSCO | |
|---|---|---|
Market Cap | $2.13B | $440.61B |
Sector | Health | Technology |
52-Week High | $20.38 | $130.00 |
52-Week Low | $7.60 | $66.20 |
Enterprise Value | $2.20B | $455.28B |
Volume | — | 22,887,319 |
Dividend Yield | — | 1.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Cisco Systems (CSCO) trades at $113.82, down 0.14% on the day, with a bearish technical signal but strong fundamentals including a 19.69% net income margin and consistent earnings beats. Recent AI cybersecurity initiatives, such as the Cisco Cloud Control platform announced June 2, 2026, are driving positive news flow. The stock shows oversold conditions with an RSI of 28.91, while analyst consensus targets $130.38.
The outlook is mixed: AI partnerships and earnings momentum support upside, but high valuation ratios (P/E 37.26) and technical resistance near $115 pose risks. Investors face volatility from competitive pressures and debt levels, though institutional buy ratings (52%) suggest confidence in long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Cisco Systems Inc
Cisco Systems, Inc. provides information technology and networking services. The Company offers enterprise network security, software development, data collaboration, cloud computing, and other related services. Cisco Systems serves customers in the United States.
Read more on CSCO →
